SCHEMBL13435188

SCHEMBL13435188

COc1cccc(CC2(Cc3cccc(OC)c3)CCCN(C3C4CC5CC(C4)CC3C5)C2=O)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
HSD11B1 P28845 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CMA1 P23946 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PKM P14618 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13435183 0.89 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MEN1KMT2AHSD11B1
SCHEMBL3421964 0.84 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2AHSD11B1
SCHEMBL13435185 0.78 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2MEN1KMT2AHSD11B1
SCHEMBL3428183 0.77 HSD11B1 (0.61) ALDH1A1SMN1; SMN2KMT2AHSD11B1GAA
SCHEMBL3421958 0.74 HSD11B1 (0.70) ALDH1A1SMN1; SMN2HSD11B1GAALMNA
SCHEMBL13435171 0.73 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2HSD11B1L3MBTL1SIGMAR1
SCHEMBL2169210 0.72 CMA1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL13461473 0.69 EGFR (0.52) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL5034230 0.69 MEN1 (0.39) ALDH1A1MEN1KMT2AGAALMNA
SCHEMBL13435180 0.68 HSD11B1 (0.55) ALDH1A1SMN1; SMN2KMT2AHSD11B1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-7687644-B2 Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-03-30 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287743-A1 Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors HSD11B1, HSD11B2, HSDL2 ALDH1A1 99/4885SMN1; SMN2 4667/4885MEN1 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.